JPMorgan analyst Anupam Rama placed shares of Ultragenyx (RARE) on “Positive Catalyst Watch” ahead of the company’s ORBIT and COSMIC study updates. The firm has confidence in setrusumab’s clinical success and keeps an Overweight rating on the shares with a $125 price target At current share levels, JPMorgan sees a “very positive” reward/risk profile heading into the updates with more win scenarios than downside scenarios.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx appoints Eric Olson Chief Business Officer
- Ultragenyx Pharmaceutical: Promising Phase 3 Results for DTX401 Reinforce Buy Rating
- Ultragenyx Pharmaceuticals: Strong Buy Rating Backed by Promising Osteogenesis Imperfecta Program and Strategic Developments
- Ultragenyx’s DTX401: Promising Phase 3 Results and Commercial Viability Support Buy Rating
- Buy Rating Affirmed for Ultragenyx Pharmaceutical: Promising Phase III Results of DTX401 Gene Therapy